Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CDK2]
Substrate: CDKN1A

Description: Cyclin-dependent kinase inhibitor 1 (p21) (CDK-interacting protein 1)(Melanoma differentiation-associated protein 6) (MDA-6).

Synonyms: CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1

Ensembl ID: ENSG00000124762

UniprotKB/SwissProt: CDN1A_HUMAN (P38936)

Function: May be the important intermediate by which p53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm. Nucleus.
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of CDKN1A

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1CDKN1ACDN1A_HUMANT57DFVTE T PLEGD 24.65%GSK3B(GSK3 beta) Phospho.ELM 7.0 ViewAnalyzing
2CDKN1ACDN1A_HUMANT57DFVTE T PLEGD 24.65%JNK1 HPRD:00298(in vitro;in vivo)  ViewAnalyzing
3CDKN1ACDN1A_HUMANT57DFVTE T PLEGD 24.65%MAPK_group Phospho.ELM 7.0 ViewAnalyzing
4CDKN1ACDN1A_HUMANS130EQAEG S PGGPG 16.33%JNK1 HPRD:00298(in vitro;in vivo)  ViewAnalyzing
5CDKN1ACDN1A_HUMANS130EQAEG S PGGPG 16.33%MAPK_group Phospho.ELM 7.0 ViewAnalyzing
6CDKN1ACDN1A_HUMANS130EQAEG S PGGPG 16.33% Swiss-Prot 55.0 View   
7CDKN1ACDN1A_HUMANS130EQAEG S PGGPG 16.33%CDK2 Phospho.ELM 7.0  ViewAnalyzing
8CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%DAPK3 Phospho.ELM 7.0  ViewAnalyzing
9CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%DAPK3 HPRD:00298(in vivo)  ViewAnalyzing
10CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%AKT_group Phospho.ELM 7.0 ViewAnalyzing
11CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%PIM1 HPRD:00298(in vitro;in vivo)  ViewAnalyzing
12CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%DAPK3 HPRD:00298(in vitro;in vivo)  ViewAnalyzing
13CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%AKT1 HPRD:00298(in vitro;in vivo)  ViewAnalyzing
14CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%AKT1(PKB) Swiss-Prot 55.0  ViewAnalyzing
15CDKN1ACDN1A_HUMANT145RKRRQ T SMTDF 20.75%PKA_group Swiss-Prot 55.0  ViewAnalyzing
16CDKN1ACDN1A_HUMANS146KRRQT S MTDFY 16.02%AKT1 HPRD:00298(in vitro;in vivo)  ViewAnalyzing
17CDKN1ACDN1A_HUMANS146KRRQT S MTDFY 16.02%PKCa(PKC alpha) Phospho.ELM 7.0 ViewAnalyzing
18CDKN1ACDN1A_HUMANS146KRRQT S MTDFY 16.02%PKC_group Swiss-Prot 55.0  ViewAnalyzing
19CDKN1ACDN1A_HUMANS146KRRQT S MTDFY 16.02%AKT_group Phospho.ELM 7.0 ViewAnalyzing
20CDKN1ACDN1A_HUMANS153TDFYH S KRRLI 19.24%DYRK1B Phospho.ELM 7.0  ViewAnalyzing
21CDKN1ACDN1A_HUMANS160RRLIF S KRKP 25.26%PKC_group Swiss-Prot 55.0 (in vitro) ViewAnalyzing